Firebrick Investor Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The company plans to market Nasodine as a nasal antiseptic/disinfectant, with sales expected to begin in the following year. Firebrick remains committed to developing Nasodine for the common cold but will explore alternative study designs due to the issues encountered in the recent trial.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
- Firebrick Receives $1.81m R&D Tax Incentive
- September 2023 Quarterly Activity Report & Appendix 4C
- Update on Nasodine Trial and Forward Plans
- Phase 3 Common Cold Trial Results
- Appendix 4E & Annual Report FY23
Later from Firebrick Pharma
- December 2023 Quarterly Activity Report & Appendix 4C
- Appendix 4D & Half-Year Financial Report to 31 December 2023
- Nasodine Nasal Spray Launch in the USA
- March 2024 Quarterly Activity Report & Appendix 4C
- Firebrick Raises $800,000 via Placement
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma